Y. Hu
机构：First Affiliated Hospital of Guangdong Pharmaceutical University, Hubei Cancer Hospital
发表论文 2 篇 · 总被引 8 次 · h-index 2
代表论文
- 77P A study to evaluate the safety, tolerability and efficacy of IBI939 in combination with sintilimab in patients with previously untreated locally advanced unresectable or metastatic PD-L1-selected non-small cell lung cancer (NSCLC) (2022 · Immuno-Oncology Technology · 被引 5)
- Correction: Overexpression of SMC4 activates TGFβ/Smad signaling and promotes aggressive phenotype in glioma cells (2022 · Oncogenesis · 被引 3)